Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of PL-ASA (Vazalore) vs Immediate Release Aspirin in Healthy Volunteers
NCT05055752Phase 1Completed
- Sponsor
- PLx Pharma Inc.
- Start
- May 2020
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of omecamtiv mecarbil in cardiovascular diseases (CVD) and pain (2 arms), sponsored by PLx Pharma Inc. Primary endpoint: Bioequivalence of single-dose acetylsalicylic acid PK at 24 hours. Started May 2020; status: completed.
02
Drugs
omecamtiv mecarbil
03
Conditions
cardiovascular diseases (CVD)pain
Beyond the preview
Go deeper on NCT05055752.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05055752.